Praxis Precision Medicines (PRAX) revenue and earnings history
Praxis Precision Medicines reported revenue of $0 for fiscal 2025 (year ended Dec 31, 2025), −100.0% on the year before, and net income of −$303M.
Revenue and net income, 7 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $0−100.0% | −$326M | −$303M | −$249M | $56K | −$249M | $33.9M | — | — | $357M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Praxis Precision Medicines (PRAX) on OQRO.
Common questions
What was Praxis Precision Medicines's revenue in fiscal 2025?
$0 for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 19, 2026. That is −100.0% on fiscal 2024 ($8.55M).
Has Praxis Precision Medicines been profitable?
It reported a net loss in 7 of the years shown (2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$35.5M in fiscal 2019.
What was Praxis Precision Medicines's free cash flow in fiscal 2025?
−$249M: operating cash flow of −$249M minus capital expenditure of $56K. OQRO calculates free cash flow this way from the two filed lines.
Where these figures come from
The SEC’s companyfacts data: every figure Praxis Precision Medicines tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
